Oct 03, 2017
Valeant Will Release Third-Quarter 2017 Financial Results On November 7
Oct 02, 2017
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
Oct 02, 2017
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
Oct 02, 2017
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes
Sep 29, 2017
Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group
Sep 27, 2017
Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans
Sep 27, 2017
Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference
Sep 15, 2017
Valeant Commits $200,000 to Support Hurricane Relief Efforts
Sep 06, 2017
Valeant To Participate At The Morgan Stanley Global Healthcare Conference
Sep 05, 2017
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
Aug 16, 2017
Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
Aug 09, 2017
Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy
Aug 07, 2017
Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA
Jul 27, 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Jul 17, 2017
Valeant Agrees To Sell Obagi Medical Products Business
Jul 13, 2017
Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018
Jul 10, 2017
Valeant Announces Q2 2017 Financial Results Date And Conference Call Details
Jul 10, 2017
Valeant Pays Down $811 Million of Senior Secured Term Loans
Jul 06, 2017
Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses
Jun 29, 2017
Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group